Seeking Alpha

Mike Havrilla's  Instablog

Mike Havrilla is an index developer, pharmacist, writer, and Co-Founder of BioMedReports.com with experience that includes online investing since August 1997 and writing for investors since April 2007 with a focus on the healthcare sector and small / micro-cap stocks. Mike holds Doctor of... More
My business:
ProActive HavRx BioFund
My blog:
BioMedReports.com FDA Calendar
My book:
ProActive HavRx Stock Indexes
  • NIVS IntelliMedia: 1Q09 EPS $0.06, Rev $29.3M 0 comments
    May 19, 2009 06:18 PM | about stocks: NIV

    NIVS IntelliMedia Technology Group (AMEX:NIV) filed its SEC form 10-Q after the market close on 5/19/09, which included a summary of 1Q09 financial results. The Company develops, produces and sells audio and video equipment and set-top box products under an established brand name in China with a customer base that includes both wholesalers and distributors of electronic products on a brand name as well as an original equipment manufacturer ("OEM") basis.

     
    Their products are distributed on a global basis, with China and Asia currently their largest markets. NIV products include digital audio systems, televisions, digital video broadcasting (DVB) set-top boxes and DVD players as well as peripheral products and accessories including remote controls, headphones and portable entertainment devices such as MP3 players.
     
    NIV posted revenue of $29.3 million for 1Q09, which represents and increase of $2.5 million from the year-ago period. The Company attributed the increase in revenue to increased product demand, market expansion efforts, and new product sales of digital equipment and LCD equipment. NIVS posted double-digit sales growth for televisions (up 37.3% from the year-ago period) and standard audio equipment (up 12.4% from the year-ago period). Sales volume growth during 1Q09 was led by televisions, which increased by 7% to 0.7 million pieces from the year-ago period.
     
    Cost of sales (including raw material, labor and manufacturing overhead) were $23.1 million for 1Q09, which is an increase of $2.7 million, or 13.3%, compared to $20.4 million during 1Q08. As a percentage of net revenue, the cost of sales for 1Q09 and 1Q08 was 78.6% and 75.9%, respectively. Gross profit for 1Q09 was $6.3 million, or 21.4% of revenues, as compared to $6.4 million, or 24.1% of revenues, during 1Q08.
     
    Net income was $2.4 million for 1Q09, which represents a decrease of $0.7 million from net income of $3.1 million during 1Q08. NIV ended 1Q09 with an unrestricted cash balance of about $2.2 million, as compared to $0.5 million year-end. The Company reported about $12.7 million in restricted cash as of 1Q09 versus $11.7 million at year-end. The restricted cash balance is held as a security deposit for the Company's recurring, short-term bank notes. The headline EPS for 1Q09 was $0.06 versus $0.11 in the year-ago period. A Pro-Active Research Group report for NIV is available at StockMediaBuzz.com on the Company's landing page.
     
    Disclosure: No positions.
    Stocks: NIV
Back To Mike Havrilla's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Full index of posts »
Latest Followers

StockTalks

  • $CFI $EXAS $CSIQ / Double-Digit Small / Micro-Cap Stock Gainers 2010 YTD / EXACT Sciences, Culp, Canadian Solar / http://bit.ly/6qucfJ
    about 13 hours ago
  • $MNKD / MannKind discussing inhaled insulin Afresa label with FDA, delay by week or so possible 4 final decision / http://bit.ly/51ZSaH
    about 13 hours ago
  • $KERX / Keryx Biopharma reaches SPA agrmt with FDA for pivotal Phase 3 studies for Zerenex for kidney disease / http://tinyurl.com/yaeuqtc
    about 19 hours ago
More »
Posts by Ticker
AAPL, ABII, ABIO, ABT, ABV, ACAD, ACCP.OB, ACOR, ACUR, ACUS, ADAM, ADLS, AET, AEZS, AFFY, AGEN, AGN, ALKS, ALNY, ALPMF.PK, ALTH, ALXA, AMAG, AMGN, AMLN, AMRN, ANPI, APPA, APPY, ARDM.OB, ARKTF.PK, ARNA, ARUXF.PK, ARYX, ATHN, AUXL, AVNR, AZN, BAX, BAYRY.PK, BCRX, BDSI, BFRM, BIIB, BIOD, BMRN, BMTI, BMY, BPAX, BSX,

Latest Comments


Most Commented
  1. BioMedReports.com Mention in BusinessWeek (7 Comments)
  2. Sequenom Splattered, EXACT Sciences on the Rise (3 Comments)
  3. Who Will Take GM's Place in the Dow? (3 Comments)
  4. 13 Extreme FDA Trades: BioMedReports.com 6/1/09 Update (3 Comments)
  5. Mentor Capital: A Stealth Cancer Immunotherapy Play (3 Comments)
Posts by Themes
allos therapeutics, ANDA, ASCO, Avastin, BIO.PA, BioAlliance, biogenerics, biomed, BioMedReports.com, biotech, BLA, Botox, cancer, cancer biotech, cancer stock, China, cholesterol, Clean Energy, Clinical Trial, Clinical Trial Calendar, Clinical Trials, clinical trials, consumer staples, Crestor, DAVANAT, defensive, Dendreon, Diabetes, Discovery Labs, dividends, Dolphin Secure, Dysport, Enablex, ETF Innovators, Extreme Trades, Facebook, FDA, fda, FDA Calendar, Feraheme, Genentech, generic, Generic Drugs, Global Pharma, GTx, Health IT, Health IT Index, healthcare, Impax Labs, Impax Pharma,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.